Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 11

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 11
---
 disclosed by the receiving party, provided that (X) the receiving
party (1) gives the disclosing party prompt written notice of such requirement prior to such disclosure and assistance in obtaining an
order protecting the information from public disclosure and (2) furnishes only that portion of the Confidential Information that is legally
required to be disclosed, and (Y) any Confidential Information so disclosed shall maintain its confidentiality protection for all purposes
other than such legally required disclosure.

(n) “”
means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.

(o) “” means the Second Amended and Restated Deposit Agreement by and among the Company, JPMorgan Chase Bank, N.A., as depositary,
and all owners and holders from time to time of American Depositary Shares thereunder.

(p) “”
means JPMorgan Chase Bank, N.A., as depositary under the Deposit Agreement.

(q) “”
means The Depository Trust Company, or any successor performing substantially the same function for the Company.

(r) “” means Depositary Shares that are (i) issued in electronic form, (ii) the resale of which is registered under an effective
registration statement and (iii) timely credited, once a DWAC notice is received, by the Company to the Investor’s or its designee’s
specified Deposit/Withdrawal at Custodian (DWAC) account with DTC under its Fast Automated Securities Transfer (FAST) Program, or any
similar program hereafter adopted by DTC performing substantially the same function.

| -3- |

(s) “” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

(t) “” means the issuance of (i) Depositary Shares, Ordinary Share Equivalents, options or other equity incentive awards
to employees, officers, directors or vendors of the Company pursuant to any equity incentive plan duly adopted for such purpose, by the
Company’s Board of Directors or a majority of the members of a committee of the Board of Directors established for such purpose,
(ii) any Securities issued to the Investor pursuant to this Agreement, (iii) any securities issued upon the exercise or exchange of or
conversion of any Depositary Shares or Ordinary Share Equivalents held by the Investor at any time, (iv) any securities issued upon the
exercise or exchange of or conversion of any Ordinary Share Equivalents that are issued and outstanding on the date of this Agreement,
provided that such securities